Surgical management of pituitary adenoma during pregnancy

Abstract

BACKGROUND

Although conservative treatment is typically recommended for pregnant patients with pituitary adenoma (PA), surgical treatment is occasionally necessary for those with acute symptoms. Currently, surgical interventions utilized among these patients is poorly studied.

AIM

To evaluate the surgical indications, timing, perioperative precautions and postoperative complications of PAs during pregnancy and to provide comprehensive guidance.

METHODS

Six patients with PAs who underwent surgical treatment during pregnancy at Peking Union Medical College Hospital between January 1990 and June 2021 were recruited for this study. Another 35 pregnant patients who were profiled in the literature were included in our analysis.

RESULTS

The 41 enrolled patients had acute symptoms including visual field defects, severe headaches or vision loss that required emergency pituitary surgeries. PA apoplexies were found in 23 patients. The majority of patients (55.9%) underwent surgery in the second trimester of pregnancy. A multidisciplinary team was involved in patient care from the preoperative period through the postpartum period. With the exception of 1 patient who underwent an induced abortion and 1 fetus that died due to a nuchal cord, 39 patients delivered successfully. Among them, 37 fetuses were healthy until the most recent follow-up.

CONCLUSION

PA surgery during pregnancy is effective and safe during the second and third trimesters. Pregnant patients requiring emergency PA surgery require multidisciplinary evaluation and healthcare management.

Key Words: Pituitary adenoma; Pregnancy; Surgery; Surgical indication; Surgical timing

Core Tip: Although clinicians generally recommend conservative treatment for patients with pituitary adenomas (PAs), surgical treatment is occasionally necessary. Currently, surgical interventions utilized among these patients is poorly studied. This study investigated the surgical interventions utilized for patients with PAs occurring during pregnancy. We found that in the second and third trimesters transsphenoidal PA surgery is a safe and effective approach for emergency conditions arising during pregnancy and may be conducted after a multidisciplinary team evaluation. These strategies may open up new avenues for the treatment of PAs during pregnancy in the future.

INTRODUCTION

Pituitary adenoma (PA) is the second most common primary brain tumor, accounting for 15% to 17% of brain tumors and 25% of benign brain tumors[1]. Although PAs can occur at any age, those occurring in pregnant patients have unique characteristics. Pregnancy can cause the enlargement of pre-existing PAs that may compress the meningeal, contributing to acute symptoms such as severe headache and visual defects. These symptoms can affect maternal health and fetal development[2]. In addition, hormone-secreting PAs may lead to increased levels of hormones, such as adrenocorticotropic hormone (ACTH) and thyroid-stimulating hormone (TSH), resulting in poor prognoses[1,3].

During pregnancy, some PAs can be controlled by conservative treatment. For example, patients with prolactinomas are treated with oral dopamine agonists (DAs)[1,4-6]. Although there is no evidence that somatostatin analogues (SSAs) are safe for the fetus during pregnancy, SSAs are effective in reducing tumor size and decreasing growth hormone (GH) and insulin-like growth factor 1 (IGF1) levels in acromegaly[7,8]. However, some pregnant patients with acute compression symptoms, such as visual defects and severe headache, as well as non-prolactinoma patients with pathologically high hormone levels may accept surgical treatment in clinical practice. Surgical treatment may also be chosen if the problem cannot be solved by conservative treatment or potential side effects rule out pharmacological treatment. These patients pose a challenge to neurosurgeons in terms of surgical timing, surgical indications, anesthesia risk and perioperative treatment. At present, few case reports on the surgical treatment of pregnant PA patients are available, and adequate knowledge and experience regarding this surgical intervention are lacking.

The pituitary specialty at the Peking Union Medical College Hospital (PUMCH) has a long history[9], and the Neurosurgery Department of PUMCH is the founding unit of the China Pituitary Adenoma Specialist Council and the China Pituitary Disease Registry Network. The endocrinology department at PUMCH is known as a leader in endocrinology[10]. In this study, we summarized the clinical presentation, imaging features, surgical indications, perioperative management and other vital considerations of 6 pregnant PA patients surgically treated at our hospital. We also included 35 similar patients reported in the literature. Our goal was to provide suggestions for the management of pregnant PA patients to physicians in neurosurgery, endocrinology, obstetrics/gynecology, ophthalmology, and other related specialties.

MATERIALS AND METHODS

Patient enrolment at PUMCH

Six pregnant patients with PAs admitted to the neurosurgery department of PUMCH between January 1990 and June 2021 were retrospectively analyzed. All patients underwent surgery for PAs during pregnancy. The data collected included clinical symptoms, imaging features, perioperative treatment, pathological classification, and postoperative follow-up. All procedures involving human participants were performed in accordance with the ethical standards of the Institutional Ethics Committee of Peking Union Medical College Hospital at the Chinese Academy of Medical Sciences and Peking Union Medical College and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.

Additional cases from the literature and data extraction

We performed a literature search using PubMed to identify relevant studies published between January 1990 and June 2021. Our search used the MeSH terms “pituitary adenoma,” “pregnancy” and “surgery.” Citation indices were used to expand the search for relevant studies. The search was limited to studies written in English and were included only when sufficient data were available. Some studies without details of cases, such as those describing clinical symptoms, imaging findings, surgical timing and specific pathology, were not included[11].

After reading and reviewing relevant literature, only patients with PAs who underwent surgery during pregnancy were included. Patients treated with conservative treatment alone as well as those who received treatment for pathological non-PA were excluded.

Patients with duplicate reports due to multiple articles published by the same clinical center at different times were manually removed. Based on the above criteria, 30 studies screened, resulting in the inclusion of 35 patients.

Statistical analysis

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software (version 22.0; IBM Corp., Armonk, NY, United States). Measurement data conforming to a normal distribution were represented by. Enumeration data were expressed as percentages or ratios. Paired-sample t-tests were used for preoperative and postoperative comparisons. Statistical significance was set at P < 0.05.

RESULTS

Clinical characteristics

Forty-one patients with PAs who underwent surgery during pregnancy were included. A summary of their clinical characteristics is provided in Table 1, which includes 6 cases from our center and 35 cases from the PubMed database. The ages of 3 patients were not reported. The age of the remaining 38 patients ranged from 21 years to 41 years, with a mean age of 29.7 ± 5.3 years.

Table 1 Basic information and clinical symptoms of pregnant patients who underwent surgery for pituitary adenoma.

Data source	Case	Age, yr	Sex	Clinical symptoms
				Headache	Vision loss	Visual field	OP	DI	HT	CS	Acromegaly
Peking Union Medical College Hospital	1	29	F	No	Bi	BTH	No	No	No	No	No
	2	36	F	Yes	Bi	BTH	No	No	No	No	No
	3	34	F	No	Bi	BTH	Yes	Yes	No	No	No
	4	32	F	No	No	No	No	No	Yes	No	No
	5	37	F	Yes	Mo	BTH	No	No	No	No	No
	6	28	F	Yes	Bi	BTH	No	No	No	No	No
Jallad et al[16]	7	25	F	Yes	No	BTH	No	No	No	No	Yes
	8	27	F	Yes	No	BTH	No	No	No	No	Yes
	9	27	F	Yes	No	BTH	No	No	No	No	Yes
Chaiamnuay et al[17]	10	39	F	Yes	No	UTH	No	No	Yes	No	No
Guven et al[18]	11	32	F	No	Bi	BTH	No	No	No	No	Yes
Zhong et al[38]	12	29	F	No	Bi	No	No	No	No	No	No
Jemel et al[19]	13	35	F	Yes	No	BTH	No	No	No	No	No
	14	30	F	Yes	Bi	BTH	No	No	No	No	No
Xia et al[20]	15	25	F	Yes	Bi	BTH	No	No	No	No	No
Yamaguchi et al[21]	16	35	F	Yes	Bi	UTH	No	No	No	No	No
Tandon et al[22]	17	27	F	Yes	Mo	BTH	No	No	No	No	No
Parihar et al[36]	18	22	F	Yes	Bi	No	No	No	No	No	No
Gondim et al[23]	19	29	F	Yes	Mo	UTH	Yes	No	No	No	No
Witek et al[24]	20	25	F	Yes	Bi	BTH	No	No	No	No	No
Kita et al[25]	21	26	F	Yes	No	BTH	No	No	No	No	No
Nossek et al[26]	22	29	F	No	Bi	No	No	No	No	No	No
	23	34	F	No	No	BTH	No	No	No	No	No
Iuliano and Laws[27]	24	28	F	Yes	No	No	No	No	No	No	No
	25	35	F	Yes	Mo	UTH	Yes	No	No	No	No
Hayes et al[28]	26	41	F	Yes	No	BTH	No	No	No	No	No
Boronat et al[52]	27	26	F	No	No	No	No	No	No	Yes	No
Abbassy et al[37]	28	38	F	Yes	No	No	No	No	No	Yes	No
Coyne et al[53]	29	22	F	No	No	No	No	No	No	Yes	No
Pinette et al[54]	30	33	F	No	No	No	No	No	No	Yes	No
Ross et al[55]	31	24	F	No	No	No	No	No	No	Yes	No
Mellor et al[51]	32	40	F	No	No	No	No	No	No	Yes	No
Karaca et al[15]	33	NA	F	No	No	No	Yes	No	No	No	Yes
Jolly et al[56]	34	30	F	No	No	No	No	No	No	Yes	No
Galvão et al[29]	35	NA	F	Yes	Bi	BTH	No	No	No	No	No
Abid et al[30]	36	25	F	Yes	Bi	BTH	No	No	No	No	No
Barraud et al[31]	37	NA	F	Yes	No	BTH	No	No	No	No	No
Freeman et al[32]	38	22	F	Yes	Mo	BTH	No	Yes	No	No	No
Lunardi et al[33]	39	21	F	Yes	Bi	BTH	No	No	No	No	Yes
Oguz et al[34]	40	26	F	Yes	No	UTH	No	No	No	No	No
O’Neal[35]	41	27	F	Yes	No	BTH	No	No	No	No	No

Bi: Binocular; BTH: Bitemporal hemianopsia; CS: Cushing syndrome; DI: Diabetes insipidus; F: Female; HT: Hyperthyroidism; Mo: Monocular; OP: Oculomotor paralysis; NA: Not available; UTH: Unilateral temporal hemianopia.

The clinical presentations of the 41 patients were as follows: visual field defects in 28 cases (68.3%) (bitemporal hemianopsia in 23 cases, unilateral temporal hemianopia in 5 cases; Figure 1); headaches in 27 cases (65.9%); vision loss in 20 cases (48.8%) (15 cases binocular, 5 cases monocular); Cushing syndrome in 7 cases (17.1%); acromegaly in 6 cases (14.6%); oculomotor paralysis in 4 cases (9.8%); diabetes insipidus in 2 cases (4.9%); and hyperthyroidism in 2 cases (4.9%).

Figure 1 Comparison of the preoperative and postoperative visual fields for Case 6. Preoperative visual field examination showed bitemporal hemianopsia, which was more severe in the left eye. Three days after surgery, examination revealed a partial temporal visual field defect in the left eye and a standard visual field in the right eye.

Image data

The imaging data of the 41 patients are shown in Supplementary Table 1. Magnetic resonance imaging (MRI) was obtained for 37 of the patients (90.2%). Contrast-enhanced MRI was performed in 3 cases (7.3%), in which 1 case was obtained before pregnancy and 2 cases were obtained during pregnancy. Cranial enhanced computed tomography was performed in 1 case (2.4%) without MRI. The tumor sizes in the 27 patients with available data ranged from 0.4 cm to 4.0 cm (average: 2.1 ± 0.9 cm). Pituitary microadenomas were found in 2 patients. Up to 92.6% of patients (25 cases) had pituitary macroadenoma.

Twenty-seven patients underwent T1 weighted imaging (T1WI), yielding hypointensity in 11.1% of cases (3/27), isointensity in 37.0% of cases (10/27), isointensity and hypointensity in 3.7% of cases (1/27), isointensity and hyperintensity in 29.6% of cases (8/27), and hyperintensity in 18.5% of cases (5/27). Three types of T1WI for cases with pituitary apoplexy were shown in Figure 2. None of the images showed hypointensity on T1WI.

Figure 2 Three typical images of pituitary adenoma apoplexy. A: Sagittal T1 weighted imaging (T1WI) showed isointensity and hyperintensity with a visible liquid level (Case 15); B: Sagittal T1WI showed mixed intensity (mainly hyperintensity) (Case 40); C: Coronal T1WI showed isointensity (Case 5).

Ten patients underwent T2 weighted imaging, yielding hypointensity in 10.0% of cases (1/10), hyperintensity in 40.0% of cases (4/10) and isointensity and hyperintensity in 50.0% of cases (5/10). Three of the four patients who underwent contrast-enhanced MRI showed no enhancement. The remaining case showed inhomogeneous enhancement.

The Knosp classification was reported in 20 patients. In 5 cases (25.0%), the classification was invasive (Knosp classification III or IV). In 15 cases (75.0%), the classification was non-invasive. Five patients were in the highest unilateral Knosp classification IV (25.0%). Two patients (10.0%) were in Knosp classification II. Nine patients (45.0%) were in Knosp classification I, and four patients (20.0%) were in Knosp classification 0.

Hormone levels

Changes in hormone levels in the 41 patients were shown in Supplementary Table 2. Complete hormone monitoring was performed in 8 of 13 patients with prolactinoma. Prolactin levels decreased after operation, and the difference was statistically significant (P < 0.05).

GH levels in 4 patients with complete hormone monitoring decreased postoperatively, although without statistical significance (P = 0.085). One patient (Case 11) had higher IGF1 on the 2^nd day after surgery. However, the IGF1 level returned to normal after 6 mo. The IGF1 difference in the other 3 patients was not statistically significant (P = 0.115).

ACTH levels of the 3 patients completing hormone monitoring increased preoperatively and sharply decreased postoperatively. The difference was statistically significant (P < 0.05). However, among 2 patients with decreased TSH levels postoperatively, the difference was not statistically significant (P = 0.308).

Perioperative conservative treatment

Perioperative conservative treatments for the 41 patients are shown in Table 2. Twenty-two patients did not receive conservative treatment. Among the remaining 19 patients, bromocriptine was used most frequently (57.9%, 11/19), including for 6 patients with prolactinoma, 3 patients with non-functioning PA, 1 patient with TSH-secreting PA, and 1 patient without pathological classification. The second most frequent preoperative drug group was glucocorticoids, including 5 patients with non-functioning PA, 1 patient with prolactinoma and 1 patient without pathological classification. Cabergoline, also a DA, ranked third with only 2 patients, including 1 patient with non-functioning PA and 1 patient with GH-secreting PA. Drugs also used for preoperative medication included sandostatin, thyroxine, propylthiouracil, alpha-methyldopa and 1-desamino-8-D-arginine vasopressin. Postoperatively, 30 patients received conservative treatment, comprising 13 cases of glucocorticoid treatment, 7 cases of thyroxine treatment, 5 cases of arginine-vasopressin treatment, and 5 cases of desmopressin treatment.

Table 2 Treatment and follow-up outcomes of pregnant patients who underwent surgery for pituitary adenoma.

Ref.	Case	Treatment				Pathology	Follow up
		Medical therapy		Operation	Delivery		M	I
		Pre	Post
Peking Union Medical College Hospital	1	Bromocriptine	No	12th W TSS	40th W CS	NF PA	ER	H
	2	No	No	32nd W TSS	Full term CS	NF PA	ER	H
	3	No	No	22nd W TSS	38th W CS	NF PA	ER	H
	4	Sandostatin	No	26th W TSS	38th W CS	TSH PA	ER	H
	5	Bromocriptine	No	35th W TSS	35th W CS	PRL PA	ER	H
	6	Prednisone, thyroxine	Prednisone, thyroxine	30th W TSS	39th W CS	NF PA	ER	H
Jallad et al[16]	7	No	No	3rd Mon TSS	38thW CS	GH PA	ER	H
	8	No	No	4th Mon TSS	16th W A	GH PA	EC	A
	9	Cabergoline	No	4th Mon TSS	39th W CS	GH PA	ER	H
Chaiamnuay et al[17]	10	Propylthiouracil, bromocriptine	No	27th W TSS	39th W CS	TSH PA	ER	H
Guven et al[18]	11	No	Octreotide	34th W TSS	34th W CS	GH PA	EC	H
Zhong et al[38]	12	No	Cortisone, thyroxine	22nd W TSS	40th W VD	NF PA	ER	H
Jemel et al[19]	13	Cabergoline, hydrocortisone	No	22nd W TSS	37th W VD	NF PA	ER	H
	14	Corticosteroids	No	24th W TSS	38th W VD	NF PA	ER	H
Xia et al[20]	15	No	No	24th W TSS	38th W CS	PRL PA	ER	H
Yamaguchi et al[21]	16	No	Methyl prednisolone	36th W TSS	37th W CS	PRL PA, Optic neuritis	ER	H
Tandon et al[22]	17	Bromocriptine	Desmopressin	36th W TSS	37th W CS	PRL PA	ER	H
Parihar et al[36]	18	No	No	20th W TSS	Full term VD	PRL PA	ER	H
Gondim et al[23]	19	Bromocriptine	Thyroxine, hydrocortisone	32nd W TSS	39th W VD	PRL PA	EC	H
Witek et al[24]	20	Bromocriptine	Hydrocortisone	20th W TSS	38th W CS	PRL PA	ER	H
Kita et al[25]	21	No	DDAVP	27th W TSS	40th W VD	NF PA	ER	H
Nossek et al[26]	22	No	No	33rd W TSS	35th W CS	PA	ER	LAS
	23	No	No	31st W TSS	40th W VD	PA	ER	H
Iuliano and Laws[27]	24	Bromocriptine, dexamethasone	No	30th W TSS	39th W CS	NF PA	ER	H
	25	Bromocriptine, dexamethasone	Levothyroxine, hydrocortisone	33rd W TSS	39th W CS	NF PA	ER	H
Hayes et al[28]	26	Corticosteroids	No	18th W TSS	Full term VD	PRL PA	ER	H
Boronat et al[52]	27	Alpha-metildopa	Metyrapone	16th W TSS	34th W VD	ACTH PA	R	H
Abbassy et al[37]	28	No	Hydrocortisone, desmopressin	18th W TSS	39th W VD	ACTH PA	ER	H
Coyne et al[53]	29	No	Hydrocortisone, desmopressin	14th W TSS	38th W VD	ACTH PA	ER	H
Pinette et al[54]	30	No	Atenolol	16th W TSS	-	ACTH PA	ER	D
Ross et al[55]	31	No	Dexamethasone	18th W TSS	37th W CS	ACTH PA	ER	H
Mellor et al[51]	32	No	Hydrocortisone	Mid-trimester TSS	34th W CS	ACTH PA	ER	H
Karaca et al[15]	33	No	No	11th W TSS	39th W CS	GH PA	ER	H
Jolly et al[56]	34	No	Hydrocortisone, metformin, labetalol, nifedipine	23rd W TSS	38th W CS	ACTH PA	ER	D
Galvão et al[29]	35	No	No	2nd trimester TSS	-	PRL PA	ER	H
Abid et al[30]	36	Bromocriptine	Lisuride hydrogen	27th W TSS	39th W VD	PRL PA	ER	H
Barraud et al[31]	37	Bromocriptine	No	4th Mon TSS	-	PRL PA	ER	H
Freeman et al[32]	38	DDAVP	Hydrocortisone, thyroxine, DDAVP	32nd W TSS	39th W VD	PRL PA	ER	H
Lunardi et al[33]	39	No	No	6th Mon TSS	Full term VD	GH PA	EC	H
Oguz et al[34]	40	No	Levothyroxine	23rd W TSS	37th W CS	PRL PA	ER	H
O’Neal[35]	41	Hydrocortisone, bromocriptine	No	29th W TSS	37th W VD	PA	ER	H

A: Abortion; ACTH: Adrenocorticotropic hormone; CS: Cesarean section; D: Death; DDAVP: 1-Desamino-8-D-arginine vasopressin; EC: Endocrine control; ER: Endocrine remission; GH: Growth hormone; H: Healthy; I: Infant; LAS: Low Apgar score; M: Maternal; NA: Not available; NF: Nonfunctional; PA: Pituitary adenoma; Post: Postoperatively; Pre: Preoperatively; PRL: Prolactin; R: Recurrence; TSH: Thyroid stimulating hormone; TSS: Transsphenoidal surgery; VD: Vaginal delivery.

Operations and pathological classifications

All 41 patients underwent transsphenoidal surgery under general anesthesia. No patients were treated with craniotomy. With the exception of 7 patients who did not report their specific gestation, the surgical gestation of the other 34 patients ranged from 11 wk to 36 wk, with an average of 25.1 ± 7.1 wk. Two cases were in the first trimester (gestation < 14 wk; 5.9%), 19 cases in the second trimester (14 wk ≤ gestation < 28 wk; 55.9%, 19/34), and 13 cases in the third trimester (gestation ≥ 28 wk; 38.2%, 13/34).

Three cases (from PubMed) did not have pathologic classification reported. There were 13 cases (34.2%) of prolactinoma, 10 cases (26.3%) of non-functioning PA, 7 cases (18.4%) of ACTH-secreting PA, 6 cases (15.8%) of GH-secreting PA, and 2 cases (5.3%) of TSH-secreting PA.

Follow-up information

Ten patients with non-functioning PA were not in remission, and twenty-six patients (63.4%) were in endocrine remission. Four patients (9.8%) were in endocrine control, and one patient (2.4%) relapsed. In terms of pregnancy outcomes, 1 patient underwent an induced abortion at 16 wk, and 1 fetus died due to a nuchal cord at 33 wk of gestation. The remaining 39 patients delivered 37 healthy fetuses successfully. One fetus died of a congenital diaphragmatic hernia within 36 h after caesarean section at 38 wk of gestation, and one fetus survived with a low Apgar score after caesarean section at 35 wk of gestation. Twenty-two patients underwent caesarean section (59.5%), and fifteen patients chose vaginal delivery (40.5%). The method of delivery was unknown for 2 patients.

Delivery gestation was not reported in 6 of the 39 patients. Of the remaining 33 patients, gestation ranged from 34 wk to 40 wk, averaging 37.8 ± 1.7 wk. Premature delivery (28 wk ≤ gestation < 37 wk) occurred in 5 cases (15.2%), and full-term delivery (37 wk ≤ gestation < 42 wk) occurred in 28 cases (84.8%).

DISCUSSION

During pregnancy, physicians may face many challenges when diagnosing and treating PAs. Although conservative treatment is recommended for most pregnant patients with PAs, some patients must accept surgery due to visual defects, severe headaches and high hormone secretion levels that cannot be alleviated after conservative treatment[7,12-15]. We summarized the data of 41 patients with PAs who underwent surgery during pregnancy. To our knowledge, this is the most comprehensive report of surgical treatment of PAs in pregnant patients.

Clinical characteristics

Here, the three most common clinical symptoms of these patients were visual field defects (68.3%), headaches (65.9%) and vision loss (48.8%). Previous studies showed that the two most common clinical symptoms of PA patients with apoplexy during pregnancy were headaches and visual impairment[19,34], which is similar to our study.

The pituitary gland and pre-existing PAs may enlarge during pregnancy[2,39], and the risk is greater in patients with macroadenomas than in those with microadenomas[1]. This observation was confirmed here. In prolactinomas, the most common type of PA, the risk of symptomatic tumor enlargement during pregnancy was 27.9% for patients with macroadenomas and only 2.2% for patients with microadenomas[40]. Although 2 patients in our study had pituitary microadenomas, their surgical indications were intractable diabetes insipidus and Cushing syndrome rather than symptomatic tumor enlargement[15,37].

Conservative treatment during pregnancy

Conservative treatment during pregnancy primarily includes DA treatment for prolactinomas[1] and SSA treatment for GH-secreting PAs[1,7]. Although there is no evidence that SSAs increase the risk of fetal malformation[6,41-43], discontinuation of all medication except DAs during pregnancy is recommended to ensure fetal health to the maximum extent possible[7,8,44]. Resuming other treatments is recommended only when symptoms leading to poor prognoses, such as visual defects or severe headaches, occur. When patients do not achieve significant remission after conservative treatment, clinicians should consider surgical treatment as soon as possible following a multidisciplinary evaluation[8,12,44]. Additionally, to ensure maternal health and fetal development, hormone deficiencies, such as glucocorticoid or thyroxine, should be treated[45].

Indications for surgery during pregnancy

Patients with macroadenomas have a higher risk of symptomatic progression during pregnancy[1]. However, the size of the PA is not the criterion. The severity of visual defects and headaches should be used as surgical indications for PA during pregnancy[12,13]. Some microadenomas are also associated with adverse effects on maternal and fetal health due to high hormone levels[46]. Based on our results, the surgical indications during pregnancy are summarized as follows.

Visual defects: PAs are more likely to compress the optic chiasm during pregnancy, leading to visual defects[2]. When conservative treatment cannot relieve visual impairment, clinicians should conduct a multidisciplinary evaluation to balance visual defects with pregnancy safety and decide whether to treat surgically as soon as possible. Although the recovery rate of the visual field can be as high as 80%[47] to 95.7%[48], the severity and duration of visual impairment are essential factors for postoperative visual prognosis. Irreversible adverse effects caused by severe visual impairment during pregnancy should be avoided[48].

Severe headache: Sudden, severe headache is the most common symptom of PA with apoplexy, primarily due to the enlargement of the PA during pregnancy, increased pressure on the sella turcica, and dural pressure[45]. Headache is often accompanied by nausea, vomiting, eye muscle paralysis and impairment of consciousness. Because severe headache can induce contractions, surgery is indicated if the multidisciplinary evaluation considers that the headache is due to mass effect and that pain medication would affect fetal health[49].

Hormonal abnormalities: Some PAs, such as ACTH-secreting PA and TSH-secreting PA, can cause ovulation disorders in women of reproductive age[50]. This type of patient should be treated before pregnancy as early as possible. Nevertheless, a few patients have unintended pregnancies after diagnosis[37,51,52] or are diagnosed during pregnancy[53-56]. High hormone secretion during pregnancy is closely related to several complications and poor prognoses[46,50]. Surgical treatment with appropriate timing is the most effective method for reducing hormone levels in such patients[12,17,44].

Operative timing during pregnancy

The timing of transsphenoidal surgery depends on the potential risks and benefits, including maternal symptoms, fetal safety and gestational weeks, which is the most critical indicator. The spontaneous abortion rate in the first trimester is approximately 12.0% vs 5.0% in the second and third trimesters[13]. The overall malformation incidence in pregnancy is 2.0% compared with 3.9% in the first trimester. The incidence of neural tube defects and preterm delivery is highest in the third trimester[57]. In our study, most patients also underwent surgery in the second trimester. Therefore, the second trimester is the best time for PA surgery[12-14,58,59].

For patients in the first trimester, the surgery should be postponed until the second trimester if possible[14,15]. For patients in the third trimester, Lynch et al[60] recommended delaying surgery to 30 wk of gestation if possible because fetal survival can reach 90% after 27 wk of gestation. In comparison, Priddy et al[14] suggested induction of labor or caesarean section at 34 wk of gestation followed by surgical treatment, if possible. However, among the 13 patients in this study who underwent surgeries in the third trimester, 12 patients and fetuses were healthy. One fetus survived with a low Apgar score, but the mother was healthy. In this regard, we suggest that the balance of symptom severity and gestational weeks should be considered in the third trimester when glucocorticoids can be administered to promote fetal lung maturation. If symptoms do not worsen significantly, a caesarean section should be performed first. However, surgical treatment should then be performed promptly if symptoms progress significantly (Figure 3).

Figure 3 Flow diagram of treatment procedures for pituitary adenoma during pregnancy.

Precautions for surgery during pregnancy

Preoperative: A professional multidisciplinary team should be established to conduct individualized evaluations prior to surgery for pregnant patients with PAs indicated for surgical treatment. The team should include neurosurgeons, endocrinologists, obstetricians, gynecologists, pediatricians and anesthesiologists[20,59]. MRI must be acquired before the surgery. Although fetal toxicity of gadolinium is not established, MRI without gadolinium enhancement is preferred and is sufficient to make a definitive diagnosis and plan the surgery. Given the teratogenicity of X-rays, computed tomography should be avoided[61].

Preoperative ophthalmic examination is also essential, including examinations of visual acuity, visual field, fundus and retinal nerve fiber layer, and optical coherence tomography of the ganglion cell complex[12]. The ophthalmic examination can roughly predict the postoperative recovery rates for visual impairment[48]. The possible visual sequelae include severe visual impairment, severe visual field defects and severe degeneration of the retinal nerve fiber layer/ganglion cell complex[12].

Preoperative fetal ultrasonography should be performed routinely to evaluate fetal health. Continuous fetal heart rate monitoring is feasible under the proper conditions[12]. The endocrine examination can assess pituitary function. If necessary, relevant deficient hormones should be supplemented. Preoperative operations such as enemas that can induce contractions should be avoided. After evaluation, patients and their families should be fully informed of the risks and benefits of surgery. Written informed consent should be obtained after weighing the advantages and disadvantages.

Perioperative: Inhaled anesthetics can reduce uterine tension and increase bleeding risk and cerebral perfusion pressure in a concentration-dependent manner[62]. Total intravenous anesthesia, which is preferred during pregnancy, does not affect uterine tension and can constrict the cerebrovascular system and maintain cerebral perfusion pressure[63]. The United States Food and Drug Administration Class B drugs such as propofol are recommended. However, Class C drugs, which have potential risks but can be used given sufficient expected benefit, should be carefully used after considering the advantages and disadvantages[58].

Intraoperative reduction of cardiac return can lead to severe complications such as hypotension, placental insufficiency and cerebral insufficiency. Therefore, surgeons should lower the left side of the patient below the right side to avoid compression of the inferior vena cava[12,13]. Although there is no optimal cerebral perfusion pressure target, it seems reasonable to control the mean arterial pressure 20% above the baseline[13]. During surgery, the use of diuretics and anticonvulsants should be avoided. If necessary, contractions should be suppressed to protect the fetus[12].

Postoperative: Fetal heart rate variation is an essential indicator of fetal health and can indicate fetal distress. Therefore, continuous fetal heart rate monitoring should be performed after the surgery[13]. If postoperative reactions such as nausea, vomiting and headache occur, Class B drugs such as pethidine can be used for symptomatic treatment. Routine ophthalmic examinations should be conducted postoperatively to evaluate visual defect recovery. If no significant improvement is observed, differential diagnoses with other diseases leading to visual impairment, such as optic neuritis, should be considered[21]. Hormone stoss therapy, neurotrophic drugs and other treatments can also be administered.

Limitations

Although this report is the largest case series of patients undergoing surgical treatment for pituitary tumors during pregnancy, limitations of this study include biases due to the retrospective study design and follow-up differences. In addition, although we have tried to include all cases, the number of cases is still relatively small. Therefore, we were unable to engage in analysis and discussion according to pathological classification. Prospective and multicenter studies with more cases are needed to further understand the surgical management of pituitary tumors during pregnancy.

CONCLUSION

The surgical treatment and perioperative management of PAs during pregnancy is complex. The surgical indications and timing issues must be well understood and carefully considered with the cooperation of neurosurgery, endocrinology, obstetrics, anesthesiology, neonatology and other related specialties. In the second and third trimesters, transsphenoidal surgery is a safe and effective approach for emergency treatment during pregnancy after evaluation by a multidisciplinary team. Additionally, for patients with irregular menstrual cycles, pituitary screening is necessary. Women of reproductive age who have been diagnosed with PAs should follow the advice of their endocrinologists and neurosurgeons before pregnancy.

ARTICLE HIGHLIGHTS

Research background

Although conservative treatment is recommended for pregnant patients with pituitary adenomas (PAs), surgical treatment is occasionally necessary for those with acute symptoms.

Research motivation

Surgical intervention among pregnant patients with PAs has been poorly studied.

Research objectives

To evaluate the surgical indications, timing, complications and perioperative precautions of surgical treatment of PAs during pregnancy and to provide comprehensive guidance.

Research methods

Six patients with PAs who underwent surgical treatment during pregnancy at Peking Union Medical College Hospital between January 1990 and June 2021 were included. Another 35 pregnant patients with PAs reported in the literature were also included. The surgical indications, timing of surgery, improvement of symptoms, postoperative complications and fetal condition were analyzed.

Research results

The 41 enrolled patients had acute symptoms including visual field defects, severe headaches or vision loss requiring emergency pituitary surgeries. PA apoplexies were found in 23 patients. The majority (55.9%) of patients underwent surgery in the second trimester of pregnancy. With the exception of 1 patient who underwent an induced abortion and 1 fetus who died due to a nuchal cord, 39 patients delivered successfully, and 37 of the fetuses were healthy at the most recent follow-up.

Research conclusions

PA surgery during pregnancy is effective and safe during the second and third trimesters. Pregnant patients requiring emergency PA surgery require multidisciplinary evaluation and healthcare management.

Research perspectives

Multicenter, large sample, randomized controlled clinical trials are still needed to improve the standardized guidelines for the surgical treatment of pituitary tumors during pregnancy.